Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks

TD Cowen analyst Tara Bancroft has maintained their neutral stance on RCKT stock, giving a Hold rating on May 8.

Tara Bancroft has given his Hold rating due to a combination of factors, balancing meaningful clinical progress with remaining execution and safety risks. The resumption of dosing in the pivotal Phase II Danon trial following the FDA’s lift of the clinical hold, under a revised protocol and enhanced immunomodulation, supports the therapeutic potential but also underscores lingering regulatory and safety uncertainties that constrain near‑term upside.

At the same time, positive signals from RP‑A601 in PKP2‑ACM, including RMAT designation and a defined go‑forward dose, highlight a valuable pipeline opportunity alongside the recently monetized priority review voucher that reinforces Rocket’s cash position. However, with key programs still in early or mid‑development, timelines stretching into 2026, and limited visibility on pivotal outcomes and commercialization paths, Tara views the risk‑reward as balanced, warranting a neutral Hold stance rather than a more aggressive rating change.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.